Form 8-K - Current report:
SEC Accession No. 0001193125-24-240603
Filing Date
2024-10-22
Accepted
2024-10-21 21:13:29
Documents
15
Period of Report
2024-10-21
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d902445d8k.htm   iXBRL 8-K 34264
2 EX-99.1 d902445dex991.htm EX-99.1 19301
6 GRAPHIC g902445g1021152604152.jpg GRAPHIC 3147
  Complete submission text file 0001193125-24-240603.txt   194232

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA ikt-20241021.xsd EX-101.SCH 2857
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE ikt-20241021_lab.xml EX-101.LAB 18738
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ikt-20241021_pre.xml EX-101.PRE 11713
17 EXTRACTED XBRL INSTANCE DOCUMENT d902445d8k_htm.xml XML 3768
Mailing Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339
Business Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339 678-392-3419
Inhibikase Therapeutics, Inc. (Filer) CIK: 0001750149 (see all company filings)

EIN.: 263407249 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39676 | Film No.: 241384483
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)